Working across the full product life cycle, GAP-f provides an umbrella function for partners across the spectrum of innovation of and access to better paediatric medicines, spanning multilateral, public, private and non-profit sectors. By removing barriers and filling gaps in paediatric treatment, this work has the potential to save millions of lives across diverse disease areas.  

Building on the achievements of its second phase (2022–2024), GAP-f has now launched its 2025–2030 Strategy, marking the third phase of the initiative. This strategy places a stronger emphasis on ecosystem strengthening, with more formalized partnerships across the paediatric landscape, including with industry.  

In particular, GAP-f will:  

co-develop paediatric formulations aligned with shared priorities;  address technical and regulatory challenges early in the development process; and  establish a consistent and accountable engagement model to promote scalable solutions.  

The private sector entities dialogue remains a key platform for advancing this agenda to collaborate in improving access to safe, effective, and affordable medicines for children.  

Webinar objectives:   

Hosted by the GAP-f in collaboration with the Access to Medicine Foundation, this private sector entities dialogue will explore key priorities, technical solutions to shared challenges, and partnership opportunities that can accelerate paediatric formulations development and access. 

Agenda:  

Opening remarks Presentation of the GAP-f 2025-2030 strategy Themed dialogue 1: building a partnership model with industry  Themed dialogue 2: regulatory and scientific pathways Breakout sessions 1: childhood cancer – launch of target product profiles and access pathways Breakout sessions 2: RSV – from research to delivery: aligning science, access and procurement Breakout sessions 3: malaria – innovation in formulations and technology transfer Breakout sessions 4: epilepsy – accelerating timely clinical development and equitable access  Closing reflections 

We invite you to be part of this collaborative dialogue and share your insights to shape the next phase of GAP-f’s work towards ensuring better medicines for children everywhere.Â